-transparent.png){kind=logo}
In mice, chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces an increase in the maximum number of [3H]spiperone binding sites in the striatum. The sensitivity of striatal protein phosphorylation to calcium plus calmodulin is also potentiated in MPTP-treated mice. These observations are associated with an enhancement of apomorphine-induced climbing behavior in the drug-treated animals. The results of this study suggest that in an animal model for Parkinson's disease, MPTP interrupts the dopamine (DA) transmission by chemically denervating the nigrostriatal neurons and through a compensatory mechanism, it increases the number of DA receptors as well as the sensitivity of protein phosphorylation to calcium plus calmodulin in mouse striatum. The latter two events may contribute to the development of DA receptor supersensitivity.
Y S Lau, and
Y K Fung
January 1985,
Progress in neuro-psychopharmacology & biological psychiatry,
Y S Lau, and
Y K Fung
May 1985,
The New England journal of medicine,
Y S Lau, and
Y K Fung
May 2012,
Neuroscience letters,
Y S Lau, and
Y K Fung
January 1990,
General pharmacology,
Y S Lau, and
Y K Fung
January 1990,
Advances in neurology,
Y S Lau, and
Y K Fung
February 1987,
Journal of the neurological sciences,
Y S Lau, and
Y K Fung
May 1985,
Research communications in chemical pathology and pharmacology,
Y S Lau, and
Y K Fung
December 1985,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Y S Lau, and
Y K Fung
June 2003,
Metabolic brain disease,
Y S Lau, and
Y K Fung
April 1989,
Sheng li ke xue jin zhan [Progress in physiology],
